Chris Boland - Avivagen Insider

VIV -- Canada Stock  

CAD 0.55  0.03  5.17%

Mr. Chris Boland was appointed as Chief Financial Officer of Avivagen Inc., with effect from July 12, 2012
  CFO Since 2012      
Boland is a Canadian chartered accountant and also holds the certified management accountant designation. Prior to his present appointment, Mr. Boland was in public practice . Earlier positions at other organizations include general manager at Canada Post Corporationrationrationration, chief financial officer and vicepresident finance at Optiwave Corporationrationrationration, director of tax and treasury, controller, at Eftia OSS, manager of financial reporting and controller at the Canadian Bank Note, and manager of financial reporting at Mitel Corporationrationrationration. He was also an auditor at the Office of the Auditor General and manager at Treasury Board.

Management Efficiency

The company has return on total asset (ROA) of (66.05) % which means that it has lost $66.05 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (896.54) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 1.27 M in total debt with debt to equity ratio (D/E) of 71.6 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Avivagen has Current Ratio of 5.31 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Found 1 records

CFO Since

John WhelenEnbridge

Entity Summary

Avivagen, Inc. develops and commercializes various products to replace antibiotics in livestock feeds to optimize the health and growth of the animals by supporting the animals own health defenses. The company was formerly known as Chemaphor, Inc. and changed its name to Avivagen, Inc. in May 2012. Avivagen operates under Drug Manufacturers - Major classification in Canada and traded on TSX Venture Exchange. It employs 16 people.Avivagen (VIV) is traded on TSX Venture Exchange in Canada. It is located in 100 Sussex Drive and employs 16 people.

Avivagen Leadership Team

David Hankinson, Executive Director
Louis Hui, Director - Business Development
Chris Boland, CFO
David Allan, Director
Amin Khalifa, Independent Director
Aubrey Dan, Director
Cameron Groome, CEO and President and Director
Vanessa Grant, Director
Andrew Basek, Director of Investor Relations
Drew Basek, Director of Investor Relations
Paul Mesburis, Lead Director
Graham Burton, Co-Founder, Director of Commercialization Science and Director
G Anthony, Independent Director

Stock Performance Indicators

Did you try this?

Run Portfolio Backtesting Now


Portfolio Backtesting

Avoid under-diversification and over-optimization by backtesting your portfolios
All  Next Launch Portfolio Backtesting

Also Currentnly Active

Purchased over 40 shares of
few hours ago
Traded for 74.96
Purchased a lot of shares of
few hours ago
Traded for 152.9
Purchased over 70 shares of
few hours ago
Traded for 36.03
Also please take a look at World Market Map. Please also try Fundamentals Matrix module to view fundamentals matrix and analyze how accounts are interrelated and interconnected with each other.